Trials / Completed
CompletedNCT00881153
To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Sandoz GmbH and Bristol-Myers Squibb Company (Cefzil) 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose In Healthy Adults Volunteers Under Fasting Conditions.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sandoz · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH) | |
| DRUG | Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb) |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2004-06-01
- Completion
- 2004-06-01
- First posted
- 2009-04-15
- Last updated
- 2017-03-29
Source: ClinicalTrials.gov record NCT00881153. Inclusion in this directory is not an endorsement.